Cullinan Therapeutics, Inc. (CGEM)
NMS – Real Time Price. Currency in USD
19.61
-0.01 (-0.08%)
Market open: Aug 12, 2026, 11:08 AM EDT
19.66
+0.03 (0.15%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Find any stock by ticker or company name

NMS – Real Time Price. Currency in USD
19.61
-0.01 (-0.08%)
Market open: Aug 12, 2026, 11:08 AM EDT
19.66
+0.03 (0.15%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
No Data
There are no news for this stock.
Company's cash reserves $78.6M significantly exceed its total debt $2.1M, ensuring strong financial flexibility
Total current assets $342.0M exceed Total current liabilities $40.6M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$38.2M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 8.42 | 6.05 | 10 | |
| Quick ratio | 8.42 | 5.63 | 10 | |
| Debt to Equity | 0.01 | 0.30 | 10 | |
| Debt to Assets | 0.01 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | -93K | -310K | -306K | -311K | -316K |
| Operating Income | -132M | -191M | -197M | -242M | -222M |
| Net Income | 111M | -153M | -167M | -220M | -205M |
| EBITDA | -132M | -190M | -197M | -241M | -221M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | -10.32 | 1.0 |
| Next quarter | N/A | 7.22 | 3.0 |
| Current year | N/A | 6.51 | 3.0 |
| Next year | 154.54 | 16.69 | 9.5 |
| Weighted average score | 4.1 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -8.13 | -7.99 | 17 | 5.3 |
| Y/Y | 999 | 23.34 | 24.3 | -4.07 | 7.8 |
| 3y average | 999 | -92.77 | -83.73 | -11.4 | 3.3 |
| 5y average | 779.2 | -7.05 | 15.52 | -54.85 | 5.3 |
| Weighted average score | 5.4 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |